Mirdametinib
- Generic Name
- Mirdametinib
- Drug Type
- Small Molecule
- Chemical Formula
- C16H14F3IN2O4
- CAS Number
- 391210-10-9
- Unique Ingredient Identifier
- 86K0J5AK6M
- Background
PD-0325901 has been used in trials studying the treatment and basic science of Melanoma, Solid Tumour, Solid Tumors, Advanced Cancer, and Breast Neoplasms, among others.
MEK Inhibitor PD-325901 To Treat Advanced Non-Small Cell Lung Cancer
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2009-03-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 34
- Registration Number
- NCT00174369
- Locations
- 🇺🇸
Pfizer Investigational Site, Philadelphia, Pennsylvania, United States
MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2013-09-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 79
- Registration Number
- NCT00147550
- Locations
- 🇺🇸
Pfizer Investigational Site, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath